These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 34471161)
1. Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1. Shahinozzaman M; Ahmed S; Emran R; Tawata S Sci Rep; 2021 Sep; 11(1):17471. PubMed ID: 34471161 [TBL] [Abstract][Full Text] [Related]
2. 1,2,3-Triazolyl ester of Ketorolac: A "Click Chemistry"-based highly potent PAK1-blocking cancer-killer. Nguyen BCQ; Takahashi H; Uto Y; Shahinozzaman MD; Tawata S; Maruta H Eur J Med Chem; 2017 Jan; 126():270-276. PubMed ID: 27889630 [TBL] [Abstract][Full Text] [Related]
3. Both triazolyl ester of ketorolac (15K) and YM155 inhibit the embryonic angiogenesis in ovo (fertilized eggs) via their common PAK1-survivin/VEGF signaling pathway. Ahn MR; Bae JY; Jeong DH; Takahashi H; Uto Y; Maruta H Drug Discov Ther; 2017; 11(6):300-306. PubMed ID: 29332887 [TBL] [Abstract][Full Text] [Related]
4. 1,2,3-Triazolyl ester of ketorolac (15K): Boosting both heat-endurance and lifespan of C. elegans by down-regulating PAK1 at nM levels. Nguyen BC; Kim SA; Won SM; Park SK; Uto Y; Maruta H Drug Discov Ther; 2018; 12(2):92-96. PubMed ID: 29760342 [TBL] [Abstract][Full Text] [Related]
5. 1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice. Hennig R; Albawardi A; Almarzooqi S; Haneefa S; Imbaraj E; Zaaba NE; Nemmar A; Subramanya S; Maruta H; Adrian TE Drug Discov Ther; 2019 Nov; 13(5):248-255. PubMed ID: 31656252 [TBL] [Abstract][Full Text] [Related]
6. From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy. Maruta H; Ahn MR Eur J Med Chem; 2017 Dec; 142():229-243. PubMed ID: 28814374 [TBL] [Abstract][Full Text] [Related]
7. 1,2,3-Triazolyl esterization of PAK1-blocking propolis ingredients, artepillin C (ARC) and caffeic acid (CA), for boosting their anti-cancer/anti-PAK1 activities along with cell-permeability. Takahashi H; Nguyen BCQ; Uto Y; Shahinozzaman M; Tawata S; Maruta H Drug Discov Ther; 2017 May; 11(2):104-109. PubMed ID: 28442677 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of p21-activated kinases (PAKs). Rudolph J; Crawford JJ; Hoeflich KP; Wang W J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869 [TBL] [Abstract][Full Text] [Related]
12. Water Mapping and Scoring Approaches to Predict the Role of Hydration Sites in the Binding Affinity of PAK1 Inhibitors. Biswal J; Jayaprakash P; Rayala SK; Venkatraman G; Rangasamy R; Poopandi S; Jeyakanthan J Comb Chem High Throughput Screen; 2022; 25(4):660-676. PubMed ID: 33687876 [TBL] [Abstract][Full Text] [Related]
13. Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. El-Baba C; Mahadevan V; Fahlbusch FB; Mohan S S; Rau TT; Gali-Muhtasib H; Schneider-Stock R Mol Cancer; 2014 Aug; 13():201. PubMed ID: 25174975 [TBL] [Abstract][Full Text] [Related]
14. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation. Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101 [TBL] [Abstract][Full Text] [Related]
15. Old drug new tricks: Chlorhexidine acts as a potential allosteric inhibitor toward PAK1. Huang HW; Zhang XY; Song PL; Jiang HL; Li W; Wang PL; Wang J; Liu FN Biochem Biophys Res Commun; 2018 Jan; 495(1):728-732. PubMed ID: 29146188 [TBL] [Abstract][Full Text] [Related]
16. [Computer-aided prediction and molecular mechanism investigation of active components in compound Kushen injection inhibiting p21-activated kinase 1]. Lin L; Chang J; Tian Y; Chen J Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2024 Apr; 41(2):313-320. PubMed ID: 38686412 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors. Gul M; Fakhar M; Najumuddin ; Rashid S PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805 [TBL] [Abstract][Full Text] [Related]
18. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Viaud J; Peterson JR Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886 [TBL] [Abstract][Full Text] [Related]
19. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Deacon SW; Beeser A; Fukui JA; Rennefahrt UE; Myers C; Chernoff J; Peterson JR Chem Biol; 2008 Apr; 15(4):322-31. PubMed ID: 18420139 [TBL] [Abstract][Full Text] [Related]
20. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain. Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]